Swiss pharmaceutical company Novartis announced Tuesday that it had discontinued the development of two drugs — the hepatitis C treatment Zalbin, and antifungal agent Mycograb. The company will take impairment charges of approximately $590 million in third quarter of 2010.
Continue reading Novartis Discontinues Two Drug Development Programs
Novartis Discontinues Two Drug Development Programs originally appeared on DailyFinance on Tue, 05 Oct 2010 12:04:00.
Filed Under: Health Care, Novartis